ð é«åžçç
ð äžé éé»
- Stenotrophomonas maltophilia:
- Gram - rod, oxidase -, non-lactose, motile
- é«é¢ water + skin colonizer; immunocompromise + ventilator + line + åç
- Intrinsic MDR (almost all β-lactams R, FQ R variable)
- TMP-SMX éŠéž (only consistently active)
- Alt: minocycline, levofloxacin, ceftazidime (if S), tigecycline
- Burkholderia cepacia complex (BCC):
- å€ species (B. cenocepacia, B. multivorans most clinical)
- CF chronic colonization â âcepacia syndromeâ (fulminant sepsis + pneumonia)
- Intrinsic MDR â TMP-SMX, ceftazidime, meropenem, minocycline alternatives
- Lung transplant â historically contraindication (some center reversed)
- Burkholderia pseudomallei â Melioidosis:
- Thailand, N Australia, SE Asia, increasingly tropics (climate change)
- Soil + freshwater
- âGreat mimickerâ â multi-organ abscess, pneumonia, septic shock
- DM, alcoholism, CKD = highest risk
- Treatment: Intensive phase: ceftazidime or meropenem ⥠2 wk IV â Eradication phase: TMP-SMX ⥠12 wk
- Burkholderia mallei â Glanders: equine zoonosis, bioterror Category B
- Achromobacter, Ralstonia, Pandoraea, Cupriavidus: rare opportunistic
1ïžâ£ Stenotrophomonas maltophilia
Microbiology
- Gram - rod, oxidase NEG (vs PsA +)
- Motile
- å€ colors / no pigment
- Non-lactose
Habitat
- Soil + water + plant + skin
- é«é¢ sinks, dialysate, IV solution contamination
- Immunocompromise + ICU vent + line
èšåº
- Bacteremia (line, immunocompromise â leukemia, BMT, ICU)
- Pneumonia (VAP, CF chronic, HSCT)
- UTI, wound, meningitis (post-NSx), endocarditis (rare)
- å€ mortality åš immunocompromise
Treatment
- Intrinsic R: most β-lactams (carbapenems too â Acinetobacter-like AmpC + L1 metallo β-lactamase)
- TMP-SMX éŠéž (é« sensitivity, intracellular concentration good)
- Minocycline â good alternative
- Levofloxacin â alternative if S
- Ceftazidime â varying S
- Cefiderocol â alternative for difficult cases
- Tigecycline â wound / abdominal but not bacteremia
- Combination sometimes for severe (TMP-SMX + levo + minocycline)
Pregnancy
- TMP-SMX contraindicated 3rd trimester (kernicterus risk in neonate)
- Alternative: minocycline (caution), levofloxacin
2ïžâ£ Burkholderia cepacia Complex (BCC)
Microbiology
- Gram - rod, oxidase +, motile, lactose +
- å€ species (B. cenocepacia, B. multivorans, B. vietnamiensis, etc.)
- B. cenocepacia (genomovar III) â most aggressive
æµè¡ç
åž
- Soil + water + plants
- é«é¢ contaminations (mouthwash, nebulizer, etc.)
- CF most clinically relevant â chronic colonization
- Person-to-person CF transmission (segregation between CF patients important)
èšåº
- CF Chronic Colonization â FEV1 decline, exacerbations
- âCepacia Syndromeâ â fulminant pneumonia + sepsis + é« mortality in CF
- Lung transplant â B. cenocepacia historical contraindication; some centers accept B. multivorans
- Non-CF: ICU, immunocompromise, granulomatous disease
Treatment
- Intrinsic R: amino glycoside, polymyxin
- Sometimes S: TMP-SMX, ceftazidime, meropenem, minocycline, levofloxacin
- AST always â variable S
- Combination therapy in severe (TMP-SMX + meropenem + tobramycin)
- Difficult to eradicate from CF lung
3ïžâ£ Burkholderia pseudomallei (Melioidosis)
Microbiology
- Gram - rod, âsafety pinâ bipolar staining (å Yersinia, plague family)
- Oxidase +
- Soil + freshwater organism
- Hardy â survives extreme conditions
æµè¡ç
åž
- Endemic Thailand, N Australia, Malaysia, Singapore, Vietnam, India, S China, Sri Lanka, Taiwan rare
- Climate change: expanding to Africa, Americas, Pacific (Hurricane Katrina, Hurricane Maria, recent outbreaks)
- 2021 US outbreak â aromatherapy spray from S Asia
- Exposure: soil contact, agricultural work, monsoon season, contaminated water
- DM, alcoholism, CKD, thalassemia = é« risk
èšåº â âGreat Mimickerâ
- Pneumonia (mild â fulminant)
- Septicemia (high mortality 40%+)
- Multi-organ abscess: liver, spleen, lung, prostate (men), parotid (Asian children)
- Genitourinary abscess: testicular (men)
- Soft tissue / skin abscess
- Bone / joint
- Neurologic: encephalitis, brain abscess
- Latent: years after exposure, âVietnamese time bombâ (returning veterans)
- 5-25% recurrence rate
Phase 1: Intensive
- Ceftazidime 2 g IV q6h (preferred å cost in endemic country)
- OR Meropenem 1 g IV q8h (severe, ICU, neuro, septic shock)
- Duration: ⥠2 weeks (longer if abscess / osteo / CNS)
- May add TMP-SMX for severe / CNS / osteo
Phase 2: Eradication
- TMP-SMX 4 tabs (DS) PO bid à 12 wk
- Long duration prevents relapse
- Doxycycline alt
- Compliance important
Mortality
- ~ 10% Australia, 30-40% Thailand (with treatment)
- Highest in septic shock
Vaccine
- In development; not yet available
- Public health: barrier (boots, gloves) for agricultural workers in endemic regions
4ïžâ£ Burkholderia mallei (Glanders)
- Equine zoonosis (horse, mule, donkey)
- Rare human disease (lab exposure, animal contact)
- Bioterror Category B
- Cutaneous, pulmonary, septicemic, chronic forms
- Treatment: same as melioidosis (ceftazidime/meropenem â TMP-SMX)
5ïžâ£ Other Nonfermenters
Achromobacter xylosoxidans
- å¶ ICU + CF
- Bacteremia, pneumonia
- Treatment: pip-tazo, ceftazidime, mero, TMP-SMX (AST-driven)
Ralstonia + Cupriavidus
- Rare; contaminated IV solutions outbreaks
- TMP-SMX, FQ, ceftazidime
Chryseobacterium / Elizabethkingia
- E. meningoseptica â neonatal meningitis
- Multi-R; vanco + rifampin + cipro (atypical combos)
Pandoraea
- CF colonization
- Rare clinical